Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia

Pain

Volumn 146, Issue 1-2, 2009, Pages 26-33

  Nagakura, Yukinori ^a   Oe, Tomoya ^a   Aoki, Toshiaki ^a   Matsuoka, Nobuya ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Animal pain model; Biogenic amine; Fibromyalgia; Muscle pain; Reserpine; Tactile allodynia

Indexed keywords

BIOGENIC AMINE; DICLOFENAC; DOPAMINE; DULOXETINE; NORADRENALIN; PRAMIPEXOLE; PREGABALIN; RESERPINE; SEROTONIN;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; COMORBIDITY; CONSTRUCT VALIDITY; CONTROLLED STUDY; DEPRESSION; FACE VALIDITY; FEMALE; FIBROMYALGIA; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; MYALGIA; NONHUMAN; PATHOPHYSIOLOGY; PREDICTIVE VALIDITY; PREFRONTAL CORTEX; PRESSURE; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SPINAL CORD; SYMPTOMATOLOGY; THALAMUS;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; BIOGENIC AMINES; CENTRAL NERVOUS SYSTEM; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; FEMALE; FIBROMYALGIA; HYPERALGESIA; MALE; MUSCLE, SKELETAL; MUSCULAR DISEASES; PAIN; PAIN THRESHOLD; PHYSICAL STIMULATION; PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; RESERPINE; SWIMMING; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 70349777305     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2009.05.024     Document Type: Article

References (63)

1. Ablin J., Neumann L., and Buskila D. Pathogenesis of fibromyalgia - a review. Joint Bone Spine 75 (2008) 273-279
2. Arendt-Nielsen L., Graven-Nielsen T., Svensson P., and Jensen T.S. Temporal summation in muscles and referred pain areas: an experimental human study. Muscle Nerve 20 (1997) 1311-1313
3. Arnold L.M. Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthritis Res Ther 8 (2006) 212
4. Barasi S., and Duggal K.N. The effect of local and systemic application of dopaminergic agents on tail flick latency in the rat. Eur J Pharmacol 117 (1985) 287-294
5. Basbaum A.I., and Fields H.L. Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci 7 (1984) 309-338
6. Bennett R.M. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 74 (1999) 385-398
7. Bradley L.A. Pathophysiologic mechanisms of fibromyalgia and its related disorders. J Clin Psychiatry 69 (2008) 6-13
8. Burgmer M., Pogatzki-Zahn E., Gaubitz M., Wessoleck E., Heuft G., and Pfleiderer B. Altered brain activity during pain processing in fibromyalgia. Neuroimage 44 (2009) 502-508
9. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53 (1994) 55-63
10. Clauw D.J., and Crofford L.J. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 17 (2003) 685-701
11. Colpaert F.C. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology 26 (1987) 1431-1440
12. Cook D.B., Lange G., Ciccone D.S., Liu W.C., Steffener J., and Natelson B.H. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol 31 (2004) 364-378
13. Crofford L.J., Rowbotham M.C., Mease P.J., Russell I.J., Dworkin R.H., Corbin A.E., Young Jr. J.P., LaMoreaux L.K., Martin S.A., and Sharma U. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52 (2005) 1264-1273
14. 3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 295 (2000) 1086-1093
15. Dworkin R.H., O'Connor A.B., Backonja M., Farrar J.T., Finnerup N.B., Jensen T.S., Kalso E.A., Loeser J.D., Miaskowski C., Nurmikko T.J., Portenoy R.K., Rice A.S., Stacey B.R., Treede R.D., Turk D.C., and Wallace M.S. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132 (2007) 237-251
16. Field M.J., Bramwell S., Hughes J., and Singh L. Detection of static and dynamic components of mechanical allodynia in rat models of neuropathic pain: are they signalled by distinct primary sensory neurones?. Pain 83 (1999) 303-311
17. Finch L., and Leach G.D. The contribution of the sympathetic nervous system to the development and maintenance of experimental hypertension in the rat. Br J Pharmacol 39 (1970) 317-324
18. Goldenberg D.L., Felson D.T., and Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 29 (1986) 1371-1377
19. Gracely R.H., Petzke F., Wolf J.M., and Clauw D.J. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 46 (2002) 1333-1343
20. Heslop K.E., and Curzon G. Depletion and repletion of cortical tissue and dialysate 5-HT after reserpine. Neuropharmacology 33 (1994) 567-573
21. Heymann R.E., Helfenstein M., and Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clin Exp Rheumatol 19 (2001) 697-702
22. Holman A.J., and Myers R.R. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 52 (2005) 2495-2505
23. Huang Q.J., Jiang H., Hao X.L., and Minor T.R. Brain IL-1 beta was involved in reserpine-induced behavioral depression in rats. Acta Pharmacol Sin 25 (2004) 293-296
24. Iyengar S., Webster A.A., Hemrick-Luecke S.K., Xu J.Y., and Simmons R.M. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 311 (2004) 576-584
25. Kehl L.J., Trempe T.M., and Hargreaves K.M. A new animal model for assessing mechanisms and management of muscle hyperalgesia. Pain 85 (2000) 333-343
26. Kulkarni S.K., and Mehta A.K. Purine nucleoside-mediated immobility in mice: reversal by antidepressants. Psychopharmacology (Berlin) 85 (1985) 460-463
27. Kulkarni S.K., and Robert R.K. Reversal by serotonergic agents of reserpine-induced hyperalgesia in rats. Eur J Pharmacol 83 (1982) 325-328
28. 3H]imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology (Oxford) 40 (2001) 290-296
29. Leith N.J., and Barrett R.J. Effects of chronic amphetamine or reserpine on self-stimulation responding: animal model of depression?. Psychopharmacology (Berlin) 72 (1980) 9-15
30. Maj J., Rogóz Z., Skuza G., and Kołodziejczyk K. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol 324 (1997) 31-37
31. Malt E.A., Olafsson S., Aakvaag A., Lund A., and Ursin H. Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord 75 (2003) 77-82
32. Marcus D.A. Current trends in fibromyalgia research. Expert Opin Pharmacother 4 (2003) 1687-1695
33. Mease P.J., Clauw D.J., Gendreau R.M., Rao S.G., Kranzler J., Chen W., and Palmer R.H. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol 36 (2009) 398-409
34. Mease P.J., Russell I.J., Arnold L.M., Florian H., Young Jr. J.P., Martin S.A., and Sharma U. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 35 (2008) 502-514
35. Mense S. Neurobiological concepts of fibromyalgia - the possible role of descending spinal tracts. Scand J Rheumatol Suppl 113 (2000) 24-29
36. Mierau J., and Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol 215 (1992) 161-170
37. Millan M.J. Descending control of pain. Prog Neurobiol 66 (2002) 355-474
38. Minor T.R., Huang Q., and Foley E.A. Cytokine-purine interactions in behavioral depression in rats. Integr Physiol Behav Sci 38 (2003) 189-202
39. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266 (1977) 730-732
40. Price D.D., Staud R., Robinson M.E., Mauderli A.P., Cannon R., and Vierck C.J. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain 99 (2002) 49-59
41. Rao S.G., and Bennett R.M. Pharmacological therapies in fibromyalgia. Best Pract Res Clin Rheumatol 17 (2003) 611-627
42. Ren K., and Dubner R. Descending modulation in persistent pain: an update. Pain 100 (2002) 1-6
43. Rooks D.S. Fibromyalgia treatment update. Curr Opin Rheumatol 19 (2007) 111-117
44. Russell I.J., Kamin M., Bennett R.M., Schnitzer T.J., Green J.A., and Katz W.A. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 6 (2000) 250-257
45. Russell I.J., Mease P.J., Smith T.R., Kajdasz D.K., Wohlreich M.M., Detke M.J., Walker D.J., Chappell A.S., and Arnold L.M. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136 (2008) 432-444
46. Russell I.J., Vaeroy H., Javors M., and Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 35 (1992) 550-556
47. Schäfers M., Sorkin L.S., and Sommer C. Intramuscular injection of tumor necrosis factor-alpha induces muscle hyperalgesia in rats. Pain 104 (2003) 579-588
48. Schuldiner S., Shirvan A., and Linial M. Vesicular neurotransmitter transporters: from bacteria to humans. Physiol Rev 75 (1995) 369-392
49. Sluka K.A., Kalra A., and Moore S.A. Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve 24 (2001) 37-46
50. Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep 4 (2002) 299-305
51. Staud R., and Rodriguez M.E. Mechanisms of disease: pain in fibromyalgia syndrome. Nat Clin Pract Rheumatol 2 (2006) 90-98
52. Suarez-Roca H., Quintero L., Arcaya J.L., Maixner W., and Rao S.G. Stress-induced muscle and cutaneous hyperalgesia: differential effect of milnacipran. Physiol Behav 88 (2006) 82-87
53. Tamae A., Nakatsuka T., Koga K., Kato G., Furue H., Katafuchi T., and Yoshimura M. Direct inhibition of substantia gelatinosa neurones in the rat spinal cord by activation of dopamine D2-like receptors. J Physiol 568 (2005) 243-253
54. Vetulani J., Antkiewicz-Michaluk L., Rokosz-Pelc A., and Michaluk J. Effects of chronically administered antidepressants and electroconvulsive treatment on cerebral neurotransmitter receptors in rodents with 'model depression'. Ciba Found Symp 123 (1986) 234-245
55. Willis W.D., and Westlund K.N. Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol 14 (1997) 2-31
56. Wolfe F., Ross K., Anderson J., Russell I.J., and Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38 (1995) 19-28
57. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M., Bombardier C., Goldenberg D.L., Tugwell P., Campbell S.M., Abeles M., Clark P., Fam A.G., Farber S.J., Fiechtner J.J., Franklin C.M., Gatter R.A., Hamaty D., Lessard J., Lichtbroun A.S., Masi A.T., Mccain G.A., Reynolds W.J., Romano T.J., Russell I.J., and Sheon R.P. The American College. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33 (1990) 160-172
58. Wood P.B. Stress and dopamine: implications for the pathophysiology of chronic widespread pain. Med Hypotheses 62 (2004) 420-424
59. Wood P.B. Role of central dopamine in pain and analgesia. Expert Rev Neurother 8 (2008) 781-797
60. Wood P.B., Holman A.J., and Jones K.D. Novel pharmacotherapy for fibromyalgia. Expert Opin Investig Drugs 16 (2007) 829-841
61. Yunus M.B. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum 36 (2007) 339-356
62. Yunus M.B., Masi A.T., and Aldag J.C. Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. J Rheumatol 16 (1989) 527-532
63. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 (1983) 109-110